Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending February 2011. The report details a specific share repurchase transaction executed on February 11, 2011, pursuant to shareholder authority granted at the Annual General Meeting on May 6, 2010.
Key Financial Metrics
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity. It focuses exclusively on capital structure and share repurchase activity.
- Shares Purchased: 900,000 Ordinary shares of 25 pence each.
- Price Range: Highest price paid was 1,181.0 pence per share; lowest price paid was 1,167.0 pence per share.
- Treasury Holdings (Settled): 477,357,284 shares (8.42% of total issued share capital).
- Treasury Holdings (Including Unsettled): 481,037,284 shares (9.26% of total voting rights).
- Shares in Issue: 5,193,419,090 shares (excluding treasury shares).
Material Changes
The primary material change reported is the reduction of outstanding shares through the purchase of 900,000 shares on February 11, 2011. Consequently, the percentage of total voting rights held in Treasury increased to 9.26% when including unsettled purchases.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. The stated intent is to hold the repurchased shares in Treasury.
Investor Verification Checklist
- Verify the total number of shares held in Treasury against the company's latest annual report to confirm the 8.42% and 9.26% figures.
- Confirm the remaining authorization limit for share buybacks under the mandate granted on May 6, 2010.
- Check the settlement status of the 3,680,000 shares (difference between settled and total treasury holdings) to understand the timing of the voting rights reduction.
- Review the Financial Services Authority's Disclosure and Transparency Rules to ensure the 5,193,419,090 share count is the correct denominator for shareholder notification thresholds.